Translate text to:
In JoVE (1)
- Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Other Publications (2)
Articles by Alexandra Chesnokova in JoVE
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Julia Y. Ljubimova1, Hui Ding1, Jose Portilla-Arias1, Rameshwar Patil1, Pallavi R. Gangalum1, Alexandra Chesnokova1, Satoshi Inoue1, Arthur Rekechenetskiy1, Tala Nassoura1, Keith L. Black1, Eggehard Holler1
1Nanomedicine Research Center, Department of Neurosurgery, Cedars-Sinai Medical Center
Other articles by Alexandra Chesnokova on PubMed
Toxicity and Efficacy Evaluation of Multiple Targeted Polymalic Acid Conjugates for Triple-negative Breast Cancer Treatment
Journal of Drug Targeting. Dec, 2013 | Pubmed ID: 24032759
Engineered nanoparticles are widely used for delivery of drugs but frequently lack proof of safety for cancer patient's treatment. All-in-one covalent nanodrugs of the third generation have been synthesized based on a poly(β-L-malic acid) (PMLA) platform, targeting human triple-negative breast cancer (TNBC). They significantly inhibited tumor growth in nude mice by blocking synthesis of epidermal growth factor receptor, and α4 and β1 chains of laminin-411, the tumor vascular wall protein and angiogenesis marker. PMLA and nanodrug biocompatibility and toxicity at low and high dosages were evaluated in vitro and in vivo. The dual-action nanodrug and single-action precursor nanoconjugates were assessed under in vitro conditions and in vivo with multiple treatment regimens (6 and 12 treatments). The monitoring of TNBC treatment in vivo with different drugs included blood hematologic and immunologic analysis after multiple intravenous administrations. The present study demonstrates that the dual-action nanoconjugate is highly effective in preclinical TNBC treatment without side effects, supported by hematologic and immunologic assays data. PMLA-based nanodrugs of the Polycefin™ family passed multiple toxicity and efficacy tests in vitro and in vivo on preclinical level and may prove to be optimized and efficacious for the treatment of cancer patients in the future.
Near-infrared Imaging of Brain Tumors Using the Tumor Paint BLZ-100 to Achieve Near-complete Resection of Brain Tumors
Neurosurgical Focus. Feb, 2014 | Pubmed ID: 24484247
The intraoperative clear delineation between brain tumor and normal tissue in real time is required to ensure near-complete resection without damaging the nearby eloquent brain. Tumor Paint BLZ-100, a tumor ligand chlorotoxin (CTX) conjugated to indocyanine green (ICG), has shown potential to be a targeted contrast agent. There are many infrared imaging systems in use, but they are not optimized to the low concentration and amount of ICG. The authors present a novel proof-of-concept near-infrared (NIR) imaging system using a standard charge-coupled device (CCD) camera for visualizing low levels of ICG attached to the tumors. This system is small, inexpensive, and sensitive. The imaging system uses a narrow-band laser at 785 nm and a notch filter in front of the sensor at the band. The camera is a 2-CCD camera, which uses identical CCDs for both visible and NIR light.